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The Journal of the American Osteopathic Association January 2016 | Vol 116 | No. 1 e2 in a monogamous, heterosexual relationship for at least 3 months in which both partners were motivated to have or attempt sexual intercourse at least 4 times per month beginning 2 weeks after the study treatment; were willing to limit alcohol intake and eliminate use of recreational drugs for sexual encounters; were willing to undergo an injection; were mentally competent and able to understand all study requirements; were willing to be available for all baseline, treatment, and follow-up examinations required by protocol; and were willing to forego participation in any other study throughout the duration of the present study. In addition, participants were not allowed to take oral phosphodiesterase-5 inhibitors for the first 6 months after receiving the study treatment, and those who were taking phosphodiesterase-5 inhibitors were required to go through a 4-week washout period to allow clearance of the drug before completion of the baseline erectile function assessments and study treatment.
Exclusion criteria were clinically evident penile anatomical deformities (eg, Peyronie disease) or a history of priapism; participation in any nonstudy intervention for ED within 4 weeks of study treatment; uncontrolled hypertension or hypotension (systolic blood pressure >170 mm Hg or <90 mm Hg and diastolic blood pressure >100 mm Hg or <50 mm Hg); untreated hypogonadism or low serum total testosterone (<200 ng/ dL); body mass index greater than or equal to 30; major medical conditions; prostate cancer; previous pelvic or abdominal radiation therapy; previous, concomitant, or scheduled use of antiandrogen therapy; skin irritation, infection, wound, sore, or disruption in the immediate areas of skin entry for penile injection; previous penile implant or penile vascular surgery; current or previous malignancy other than localized prostate cancer; unstable cardiovascular disease (eg, unstable angina, myocardial infarction within the past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart failure); symptomatic postural hypotension within 6 months before screening; current urinary tract or bladder infection; systemic autoimmune disorder; substantial active systemic or localized infection; immunoMultipotent mesenchymal stem cells can form in the embryonic lineage to which they belong. 5 These cells can originate from fetal tissue, umbilical cord blood, or adult tissues and have been found in placenta, amniotic fluid, adipose tissue, liver, muscle, and umbilical cord blood. 6, 7 Mesenchymal stem cells may also exert beneficial effects through a paracrine-dependent fashion to assist in local growth and regeneration of the tissue in which they reside. 6, 7 Animal models have demonstrated that intracavernosal injections of autologous and allogenic mesenchymal stem cells improve erectile functions in rats with cavernous nerve injury by increasing the mean maximum intracavernosal pressure. 8 Intracavernosal transplant of bone marrow-derived mesenchymal stem cells in rats with diabetes had beneficial effects compared with controls by increasing the content of endothelium and smooth muscle in the corpus cavernosum. The present study seeks to determine the feasibility of using placental matrix-derived mesenchymal stem cells (PM-MSCs) in the management of ED in humans.
Methods
The PM-MSCs in this study, which are thought to increase vasculogenesis and ultimately improve penile blood flow, were derived from the chorionic placenta. We recruited Baseline EDV was measured in each of the 8 patients after the trimix injection. At 6 weeks, 3 months, and 6 months after PM-MSC injection, the change in EDV was not found to be statistically significant. The Table   demonstrates the 8 patients' PSV, EDV, SPL, penile width, and IIEF scores from baseline over the course of 6 weeks, 3 months, and 6 months, respectively. Increases in PSV reached statistical significance at 3 months and 6 months. At 6 weeks, 3 months, and 6 months, the changes in IIEF scores, SPL, and penile width were not statistically significant.
Before this study, all 8 patients required injectable medications to achieve erections. After PM-MSC injection, 3 patients were able to achieve erections with no Statistical analysis was calculated with statistical significance set at P<.05. Unpaired t tests and a 2-tailed P value were calculated for each measured PSV, EDV, SPL, penile width, and IIEF scores.
Results
In total, 8 patients were enrolled in the study. All of the patients had been using injectable medications to sustain an erection. All but 1 of these patients passed the rigidity testing after the trimix injection.
Baseline PSV was measured in each of the 8 patients after trimix injection (Table) and initially ranged We believe it is unlikely that 1 injection of any substance would be able to restore erectile function completely, but this treatment may help maximize penile blood flow and improve erectile function.
A limitation of the present study is the small sample size (n=8) and smaller sample at the 6-month follow-up (n=5). Further investigations should study a larger population to determine whether the results of the current study are consistent and to examine long-term outcomes.
In addition to a larger population, randomized doubleblinded controlled trials need to be conducted to evaluate efficacy, safety, and adverse outcomes over long-term follow-up at 1 year and 5 years.
Conclusion
To our knowledge, the present study is one of the first human studies to report on the feasibility of using stem cell therapy to manage ED. We believe this treatment may be especially beneficial to men who have been unable to achieve erections after oral medications. Although the results of the present study appear promising, stem cells and other biologic products must be further evaluated to understand the precise mechanism of action of these injections. The placental matrix comprises stem cells from the chorionic layer of the amniotic sac, which also contains growth factors. Further studies should evaluate whether it was the stem cells, growth factors within the cells, or both that led to the improvement in erectile function.
